DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aurobindo Pharma Limited — Analysts/Institutional Investor Meet/Con. Call Updates

NSE 1 hr ago·13 Aug 2026, 12:35 pm

Aurobindo Pharma

Aurobindo Pharma has released the transcript from its recent institutional investor meeting. This document provides a detailed account of the discussions held with analysts and investors regarding the company's performance and future outlook.

For investors, the transcript offers valuable insights into management's strategy and their assessment of market conditions. It helps clarify the company's guidance and provides context to recent financial results, allowing shareholders to better understand the drivers behind the stock's performance.

Investors should focus on the management's commentary regarding their product pipeline and operational efficiency. Monitoring how the company addresses market challenges in the transcript will be key to understanding its competitive positioning and potential for growth in the coming quarters.

Affected stocks

Neutral1 stock

Aurobindo Pharma

AUROPHARMA Neutral

₹1,667.00

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Aurobindo Pharma (AUROPHARMA).
Category: Company.

Why it matters

A routine update for Aurobindo Pharma. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NSE.

More Company news

More news

Company SEBI

Notice(s) of Attachment dated August 11, 2026 issued under RC No. 9205 of 2026 drawn against Nayan Mahendrabhai Thakkar in the matter of Trading activities of certain entities in the scrip of DU Digital Technologies Limited (now DU Digital Global Limited)

SEBI · 17 min ago